|1.||Fehlings, Michael G: 14 articles (12/2015 - 01/2002)|
|2.||Chen, Suzie: 12 articles (05/2015 - 03/2007)|
|3.||Goydos, James S: 10 articles (02/2015 - 03/2007)|
|4.||Coric, Vladimir: 8 articles (08/2015 - 05/2003)|
|5.||Pittenger, Christopher: 7 articles (08/2015 - 09/2005)|
|6.||Miller, R G: 7 articles (10/2009 - 01/2000)|
|7.||Sanacora, Gerard: 6 articles (08/2015 - 09/2005)|
|8.||Wall, Brian A: 6 articles (01/2015 - 03/2007)|
|9.||Meininger, V: 6 articles (03/2014 - 12/2000)|
|10.||Lacomblez, L: 6 articles (03/2014 - 12/2000)|
|1.||Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
11/07/2003 - "These results suggest that riluzole, a drug used in amyotrophic lateral sclerosis (ALS), might be beneficial for the treatment of MS."
11/01/2013 - "Riluzole is a drug approved for the treatment of amyotrophic lateral sclerosis (ALS) and may be effective for the treatment of other neurodegenerative and neuropsychiatric disorders. "
10/15/2013 - "Although riluzole is FDA approved and has been shown to be safe and effective in the context of amyotrophic lateral sclerosis, its efficacy and safety in the context of CSM remain unknown. "
05/01/2013 - "In an attempt to determine the mechanisms by which riluzole exerts neuroprotective effects, in particular to dissect the relative contributions of inhibition of glutamatergic transmission and Na+ channel modulation, the present study utilized a combination of cortical and peripheral axonal excitability approaches to monitor changes in excitability and function in patients with amyotrophic lateral sclerosis. "
01/01/2013 - "Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan."
|2.||Melanoma (Melanoma, Malignant)
01/01/2015 - "Preclinical studies have demonstrated the ability of riluzole to act as a radiosensitizing agent in melanoma. "
11/24/2010 - "This identified 44 unique compounds, including the FDA-approved drug riluzole, which is presently in clinical trials for treating melanoma. "
06/01/2009 - "We have now completed a phase 0 trial of riluzole in patients with melanoma. "
06/01/2009 - "A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma."
03/01/2014 - "Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells."
01/01/2005 - "Moreover, the therapeutic efficacy of riluzole, the only drug proven to slow disease progression in ALS, is most likely related to its anti-excitotoxic properties. "
05/01/2008 - "An association study of riluzole serum concentration and survival and disease progression in patients with ALS."
11/01/2014 - "Riluzole is the only drug that slows disease progression. "
05/01/2011 - "Many compounds have been tested in laboratory-based models and in patients with ALS, but so far only one drug, riluzole, has shown efficacy, yet it only slightly slows disease progression. "
03/01/2011 - "Significant progress in understanding the cellular mechanisms of motor neuron degeneration in ALS has not been matched with the development of therapeutic strategies to prevent disease progression, and riluzole remains the only available therapy, with only marginal effects on disease survival. "
|4.||Spinal Cord Injuries (Spinal Cord Injury)
02/01/2014 - "A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury."
01/01/2015 - "Currently, an international, multi-center clinical trial (Riluzole in Acute Spinal Cord Injury Study: RISCIS) in phase II/III is in progress with riluzole for patients with SCI (clinicaltrials.gov, registration number NCT01597518). "
02/01/2014 - "A prospective, multicenter phase I trial was undertaken by the North American Clinical Trials Network (NACTN) to investigate the pharmacokinetics and safety of, as well as obtain pilot data on, the effects of riluzole on neurological outcome in acute spinal cord injury (SCI). "
09/01/2012 - "Based on these findings, riluzole has attracted considerable interest as a potential neuroprotective drug for the treatment of SCI. Currently, a Phase I trial evaluating the safety and pharmacokinetic profile of riluzole in human SCI patients is being conducted by the North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury. "
01/01/2015 - "Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside."
11/10/2000 - "We investigated the efficacy of low dose riluzole, which was similar to the dose used in human trials, in animal model of global ischemia. "
09/01/2010 - "In ET group and riluzole group, Nav1.1 expression were down-regulated compared with that in MCAO group after ischemia, the infarct volume was smaller than that in MCAO group at the same time point, and the difference is significant (p<0.05); however, the difference between ET group and riluzole group is not significant (p>0.05). "
11/10/2000 - "Riluzole (0.8 mg/kg) were injected intraperitoneally 30min before ischemia. "
11/10/2000 - "Neuroprotective effect of low dose riluzole in gerbil model of transient global ischemia."
11/01/2000 - "The data indicate that treatment with riluzole can increase the tolerance of spinal cord motoneurons to a period of normothermic ischemia. "
|1.||Glutamic Acid (Glutamate)
|6.||Sodium Channels (Sodium Channel)
|8.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|10.||Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)